These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 21048784)

  • 21. Safety of menopausal hormone therapy in breast cancer survivors older than fifty at diagnosis: A systematic review and meta-analysis.
    Mudhune GH; Armour M; McBride KA
    Breast; 2019 Oct; 47():43-55. PubMed ID: 31344603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Putative growth characteristics of micrometastatic breast cancer.
    Chambers AF; Goss PE
    Breast Cancer Res; 2008; 10(6):114. PubMed ID: 19090969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour dormancy: findings and hypotheses from clinical research on breast cancer.
    Demicheli R
    Semin Cancer Biol; 2001 Aug; 11(4):297-306. PubMed ID: 11513565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual HER2 Blockade Helps Prevent Breast Cancer Return.
    Cancer Discov; 2017 Aug; 7(8):790. PubMed ID: 28588061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How can we integrate the biology of breast cancer cell dormancy into clinical practice?
    Elkholi IE; Rose AAN; Aguirre-Ghiso JA; Côté JF
    Cancer Cell; 2024 Jul; 42(7):1147-1151. PubMed ID: 38906154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer dormancy: from mice to man.
    Marches R; Scheuermann R; Uhr J
    Cell Cycle; 2006 Aug; 5(16):1772-8. PubMed ID: 16929181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology.
    Karlsson E; Appelgren J; Solterbeck A; Bergenheim M; Alvariza V; Bergh J
    Eur J Cancer; 2014 Nov; 50(17):2916-24. PubMed ID: 25241230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Cancer Cell Dormancy.
    Recasens A; Munoz L
    Trends Pharmacol Sci; 2019 Feb; 40(2):128-141. PubMed ID: 30612715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dormancy in Breast Cancer.
    Dalla E; Sreekumar A; Aguirre-Ghiso JA; Chodosh LA
    Cold Spring Harb Perspect Med; 2023 Nov; 13(11):. PubMed ID: 37037598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
    Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
    Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant resistance and early-breast cancer: should we change treatment strategies?
    Galmarini CM; Tredan O; Galmarini FC
    Cancer Metastasis Rev; 2014 Mar; 33(1):271-83. PubMed ID: 24346157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
    Yamashiro H; Iwata H; Masuda N; Yamamoto N; Nishimura R; Ohtani S; Sato N; Takahashi M; Kamio T; Yamazaki K; Saito T; Kato M; Lee T; Kuroi K; Takano T; Yasuno S; Morita S; Ohno S; Toi M;
    Breast Cancer; 2020 Jul; 27(4):631-641. PubMed ID: 32060785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab-based combination therapy for breast cancer.
    Montemurro F; Valabrega G; Aglietta M
    Expert Opin Pharmacother; 2004 Jan; 5(1):81-96. PubMed ID: 14680438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms governing metastatic dormancy in breast cancer.
    Dittmer J
    Semin Cancer Biol; 2017 Jun; 44():72-82. PubMed ID: 28344165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic implications from a mathematical model characterizing the course of breast cancer.
    Slack NH; Blumenson LE; Bross ID
    Cancer; 1969 Nov; 24(5):960-71. PubMed ID: 4982121
    [No Abstract]   [Full Text] [Related]  

  • 37. [Principal strategy for metastatic breast cancer].
    Sasaki M; Mukai H
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():577-80. PubMed ID: 23350466
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy.
    Spiliotaki M; Mavroudis D; Kapranou K; Markomanolaki H; Kallergi G; Koinis F; Kalbakis K; Georgoulias V; Agelaki S
    Breast Cancer Res; 2014 Nov; 16(6):485. PubMed ID: 25432416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current treatment of HER 2+ metastatic breast cancer.
    Burcombe R
    Br J Nurs; 2017 Sep; 26(Sup16a):S7-S14. PubMed ID: 28981328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor dormancy and cancer stem cells: two sides of the same coin?
    Kleffel S; Schatton T
    Adv Exp Med Biol; 2013; 734():145-79. PubMed ID: 23143979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.